Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-093-4 | CAS number: 176969-34-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 009
- Report date:
- 2009
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, 97633 Sulzfeld
- Age at study initiation (administration): 42 +/- 1 day
- Mean weight at study initiation: males 188 g, females 138 g
- Housing: 5 animals per cage in H-Temp (PSU) cages
- Diet: ground Kliba maintenance diet mouse/rat “GLP”, meal, supplied by Provimi Kliba SA, Kaiseraugst, Switzerland, ad libitum
- Water: drinking water (from water bottles), ad libitum
- Acclimation period: 7 d
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- DIET PREPARATION
For each concentration, the test substance was weighed out and mixed with a small amount of food. Then corresponding amounts of food, depending on dose group, were added to this premix in order to obtain the desired concentrations. Mixing was carried out for about 10 minutes in a laboratory mixer. The test-substance preparations were mixed weekly. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The HPLC analyses of the test-substance preparations were carried out at the Analytical Chemistry Laboratory of Experimental Toxicology and Ecology of BASF SE, Ludwigshafen, Germany. The stability of the test substance in the diet over a period of up to 12 days at room
temperature was proven before the start of the study. - Duration of treatment / exposure:
- 91/ 92 days
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0, 100, 300, 1000 mg/kg bw/ d
Basis:
nominal in diet
- Remarks:
- Doses / Concentrations:
0, 94.6, 285.7, 953.6 mg/kg bw/ d in males; 0, 98.8, 295.1 and 983.1 mg/kg bw/ d in females
Basis:
actual ingested
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, plain diet
- Details on study design:
- - Dose selection rationale: By request of the sponsor, the following dose levels adjusted in the diet were selected for the present study:
1000 mg/kg body weight/day: as high dose, which is the limit dose according to the test guidelines
300 mg/kg body weight/day: as mid dose
100 mg/kg body weight/day: as low dose
The oral route was selected since this has been proven to be suitable for the detection of a
toxicological hazard.
- Post-exposure recovery period in satellite groups: no
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
All animals were checked daily for any clinically abnormal signs. Abnormalities and changes were documented for each animal. A check for moribund and dead animals was made twice daily on working days and once daily on Saturdays, Sundays and public holidays. If animals were in a moribund state, they were sacrificed and necropsied.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: prior to the administration period and thereafter at weekly intervals.
BODY WEIGHT: Yes / No / No data
- Time schedule for examinations:
FOOD CONSUMPTION AND COMPOUND INTAKE:
Group food consumption was determined weekly for each cage. The average food consumption/cage was used to estimate the mean food consumption in grams per animal and day. The mean daily intake of test substance (group means) was calculated based upon individual values for body weight and food consumption.
FOOD EFFICIENCY:
Food efficiency (group means) was calculated based upon individual values for body weight and average food consumption for animals in each cage
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: d-1 and d90
- Dose groups that were examined: control and high dose animals
HAEMATOLOGY AND CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: morning of d92/d93
- Anaesthetic used for blood collection: Yes: isoflurane
- Animals fasted: Yes
- How many animals: all
- Parameters checked:
Hematology
Leukocyte count (WBC), Erythrocyte count (RBC), Hemoglobin (HGB), Hematocrit (HCT), Mean corpuscular volume (MCV), Mean corpuscular hemoglobin (MCH), Mean corpuscular hemoglobin concentration (MCHC), Platelet count (PLT), Differential blood count, Reticulocytes and Prothrombin time (Hepato Quick’s test) (HQT)
Clinical chemistry
Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), γ-Glutamyltransferase (GGT), Sodium (NA), Potassium (K), Chloride (CL), Inorganic phosphate (INP), Calcium(CA), Urea (UREA), Creatinine (CREA), Glucose (GLUC), Total bilirubin (TBIL), Total protein
(TPROT), Albumin (ALB), Globulins (GLOB), Triglycerides (TRIG), Cholesterol (CHOL), Magnesium (MG)
URINALYSIS: Yes
- Time schedule for collection of urine: d91/d92
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Parameters checked: pH, Protein, Glucose, Ketones, Urobilinogen, Bilirubin, Blood, Specific gravity, Sediment, Color, turbidity, Volume
NEUROBEHAVIOURAL EXAMINATION: Yes (FOB, MA)
- Time schedule for examinations: d84-d87
- Dose groups that were examined: all
- Battery of functions tested:
FOB: Home cage observations, Open field observations, Sensorimotor Tests/Reflexes
MA for 1 hour - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
The animals were sacrificed by decapitation under Isoflurane anesthesia. The exsanguinated animals were necropsied and assessed by gross pathology.
Organ weights
1. Anesthetized animals
2. Liver
3. Kidneys
4. Adrenal glands
5. Testes
6. Epididymides
7. Ovaries
8. Uterus
9. Spleen
10. Brain
11. Heart
12. Thymus
13. Thyroid glands
Organ/Tissue fixation
1. All gross lesions
2. Salivary glands (mandibular and sublingual glands)
3. Esophagus
4. Stomach (forestomach and glandular stomach)
5. Duodenum, jejunum and ileum
6. Cecum, colon and rectum
7. Liver
8. Pancreas
9. Brain
10. Pituitary gland
11. Sciatic nerve
12. Spinal cord (cervical, thoracic and lumbar cords)
13. Eyes with optic nerve
14. Adrenal glands
15. Thyroid glands
16. Parathyroid glands
17. Trachea
18. Lungs
19. Pharynx
20. Larynx
21. Nose (nasal cavity)
22. Aorta
23. Heart
24. Bone marrow (femur)
25. Lymph nodes (mesenteric and axillary lymph nodes)
26. Spleen
27. Thymus
28. Kidneys
29. Urinary bladder
30. Testes
31. Ovaries
32. Oviducts, uterus and vagina
33. Epididymides, prostate and seminal vesicle including coagulation gland
34. Female mammary gland
35. Skin
36. Skeletal muscle
37. Sternum with marrow
38. Femur with knee joint
39. Extraorbital lacrimal glands
HISTOPATHOLOGY: Yes
Fixation was followed by histotechnical processing, examination by light microscopy and assessment of findings according to the table at "Any other information on materials". - Statistics:
- Body weight, body weight change: A comparison of each group with the control group was performed using DUNNETT's test (two-sided) for the hypothesis of equal means
Urinalysis, (except color, turbidity, volume and specific gravity): Pairwise comparison of each dose group with the control group using FISHER's exact test for the hypothesis of equal proportions.
Feces, rearing, grip strength forelimbs, grip strength hindlimbs, footsplay test, motor activity, clinical pathology parameters, urine volume, urine specific gravity, organ weights: Non-parametric one-way analysis using KRUSKAL-WALLIS test (two-sided). If the resulting p-value was equal or less than 0.05, a pairwise comparison of each dose group with the control group was performed using the WILCOXON test for the hypothesis of equal medians.
Results and discussion
Results of examinations
- Details on results:
- CLINICAL SIGNS AND MORTALITY
No animal died prematurely in the present study.
BODY WEIGHT AND WEIGHT GAIN
No substance-related significantly changes in body weight as well as body weight change were measured in treated animals when compared to controls.
The apparently lower body weight and body weight change in males of group 2 (300 mg/kg) were not dose dependent and thus considered to represent normal biological variability rather than a relation to treatment.
FOOD CONSUMPTION AND COMPOUND INTAKE
Variations of daily food consumption were observed in all groups including controls.
Differences between food consumption of control and treated groups did not display a consistent pattern. In addition, no significantly differences were observed. Therefore the observed changes were not considered to be related to treatment.
The approximate, mean daily test-substance intake in mg/kg body weight/day over the entire study period is shown in the following table:
Target dose Real mean daily test-substance intake
(mg/kg bw/day) (mg/kg bw/day)
Males Females
100 94.6 98.8
300 285.7 295.1
1000 953.6 983.1
FOOD EFFICIENCY
During numerous time intervals, food efficiency differed from controls (increased/ decreased values) in all treatment groups. However, as there was no consistent trend, these deviations were considered incidental.
WATER CONSUMPTION
No test-substance influence on water consumption was observed.
OPHTHALMOSCOPIC EXAMINATION
Cornea opacity of the right eye was observed in 1/10 males of group 3 (1000 mg/kg bw/day) on days 91 and 92. Due to the isolated occurrence this observation was assessed as spontaneous in nature and therefore not substance-related.
HAEMATOLOGY
No treatment-related changes in the hematological parameters including coagulation values were measured.
At the end of the study the prothrombin time (Hepato Quick’s time) was increased in females of the 300 mg/kg bw/day dose group. This increase was not dose-dependent. The mean of the prothrombin time was within the historical control range (26.3 - 37.9 seconds). Therefore, this change was regarded as incidental rather than treatment-related.
In females of the 300 and 1000 mg/kg bw/day dose groups the absolute eosinophil counts were marginally lower compared to controls, but within the historical control range (0.06 –0.12 G/L). Furthermore, this decrease was not accompanied by any change of the total white blood cell counts (WBC). Therefore, this change was regarded as incidental rather than treatment-related.
CLINICAL CHEMISTRY
No treatment-related, adverse changes in the clinical chemistry parameters were measured.
In males of the 1000 mg/kg bw/day dose group the triglyceride values were statistically significantly higher compared to controls. This was the only parameter in clinical pathology which was deviated in dosed males and furthermore, no treatment-related histophathological finding in the liver was observed. Therefore, these higher triglyceride values were regarded as treatment-related, but not adverse.
URINALYSIS
No treatment-related, adverse changes in the urinalyses parameters were observed.
In females of the 300 mg/kg bw/day dose group the urine volume was decreased and the urinary specific gravity was increased. Both parameters were not dose-dependently changed.
Moreover, a higher specific gravity is indicating an adaptive concentrating capacity of the kidneys during a reduced urine flow rate. Therefore, these deviations were regarded as non-adverse. Furthermore, as the changes were not dose related, a relation related to treatment is unlikely.
In 7 of 10 males of the 1000 mg/kg bw/day dose group – and in one male of the 300 mg/kg bw/day dose group – the urine was daffodil-like (intense yellow) discolored. The discoloration may be due to the excretion of the test article and/or its metabolite. Since no other changes in clinical pathology parameters were found. Therefore, this change of urine color was regarded as treatment-related, but not adverse.
NEUROBEHAVIOUR
FOB
Deviations from "zero values" were obtained in several animals. However, as all findings were equally distributed between treated groups and controls, were without a dose-response relationship or occurred in single animals only, these observations were considered to have been incidental.
Besides this, the following examinations were carried out within the FOB and were assessed individually:
Home cage observations: No substance-related findings were observed.
Open field observations: No substance-related findings were observed.
Sensorimotor tests/reflexes: No substance-related findings were observed.
Quantitative parameters: No substance-related findings were observed.
MA
Regarding the overall motor activity, no significant deviations were observed.
Comparing the single intervals with the control groups, the isolated significantly decrease of interrupts in males of group 1 (100 mg/kg bw/day) at interval 10 with the lack of a doseresponse relationship is considered as spontaneous in nature and therefore not substance related.
ORGAN WEIGHTS, GROSS PATHOLOGY AND HISTOPATHOLOGY
No test item-related effects were seen on organ weights, and no macroscopic or histopathological changes considered to be test item-related were observed in the organs and tissues evaluated in this study.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- >= 953.6 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: corresponding to 983.1 mg/kg bw/d in females; no adverse effects observed up to the highest dose tested (1000 mg/kg bw/ d nominal)
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Although ECHA is providing a lot of online material in your language, part of this page is only in English. More about ECHA’s multilingual practice.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
the-echa-website-uses-cookies
find-out-more-on how-we-use-cookies